FDA MedWatch - February 2014 Drug Safety Labeling Changes includes 35 products with revisions to Prescribing Information

MedWatch logoMedWatch - The FDA Safety Information and Adverse Event Reporting Program

February 2014 Drug Safety Labeling Changes includes 35 products with revisions to Prescribing Information

The MedWatch February 2014 Safety Labeling Changes posting includes 35 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.

The "Summary Page" provides a listing of product names and safety labeling sections revised:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm388717.htm

The following drugs had modifications to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections:

Promacta (eltrombopag)
Nizoral (ketoconazole)
Bravelle (urofollitropin for injection, purified)
Juvisync (sitagliptin and simvastatin)
Menopur (menotropins for injection)
Mevacor (lovastatin)
Samsca (tolvaptan)
Vytorin (ezetimibe/simvastatin)
Zocor (simvastatin)
Afinitor (everolimus)
Afinitor Disperz (everolimus tablets for oral suspension)
Agrylin (anagrelide hydrochloride)
Aloxi (palonosetron hydrochloride)
Astagraf XL (tacrolimus extended-release capsules)
Imuran (azathioprine)
Lodosyn (carbidopa)
Simponi Aria (golimumab)
Victrelis (boceprevir)
Zelboraf (vemurafenib)
Biltricide (praziquantel)
Juxtapid (lomitapide)
Nexium (esomeprazole magnesium)
Nexium I.V. (esomeprazole sodium)
Prilosec (omeprazole)
Prilosec (omeprazole magnesium)
Vimovo (naproxen/esomeprazole magnesium)
Xarelto (rivaroxaban)
Zegerid (omeprazole/sodium bicarbonate)


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery